Clinical Trial Update: Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating transplantation using Zevalin (ibritumomab tiuxetan) with BEAM conditioning in patients with refractory diffuse large B-cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED